

# A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

NCT07081646

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Alexion Pharmaceuticals, Inc.
Enrollment	91 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Confirmed histopathological diagnosis of AL amyloidosis
  - One or more organs currently or historically impacted by AL amyloidosis according to consensus guidelines
  - Measurable hematologic disease: dFLC  $\gt$  20 mg/L or serum M-protein  $\gt$  5g/L
  - Relapsed disease or refractory disease defined as a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.
  - ECOG performance status of 0 to 1
- ... and 2 more (see full listing online)

### Exclusion (13)

- Have any other form of amyloidosis other than AL amyloidosis
  - Mayo Stage IIIb AL amyloidosis
  - Oxygen saturation  $\lt$  95% on room air
  - Systolic blood pressure  $\lt$  100mmHg
  - NYHA class III or IV
- ... and 8 more (see full listing online)

## Locations (18 total)

---

Research Site, Phoenix, Arizona, United States  
Research Site, San Francisco, California, United States  
Research Site, Tampa, Florida, United States  
... and 15 more locations